甲氨蝶呤片联合艾拉莫德片治疗类风湿关节炎的效果观察  

Effect observation of methotrexate tablets combined with iguratimod tablets on rheumatoid arthritis

作　　者：宋良月 崔旭红[1] 赵东肖[1] SONG Liang-yue;CUI Xu-hong;ZHAO Dong-xiao(Shenyang Fourth People's Hospital,Shenyang 110034,China)

机构地区：[1]沈阳市第四人民医院,110034

出　　处：《中国实用医药》2022年第25期160-162,共3页China Practical Medicine

摘　　要：目的 分析甲氨蝶呤片联合艾拉莫德片治疗类风湿关节炎的效果。方法 500例类风湿关节炎患者为研究对象,随机分为对照组和实验组,每组250例。对照组给予甲氨蝶呤片治疗,实验组给予甲氨蝶呤片联合艾拉莫德片治疗。比较两组治疗效果、实验室指标、疼痛评分及不良反应发生情况。结果 实验组治疗总有效率为95.20%,高于对照组的90.00%,差异有统计学意义(P<0.05)。治疗后,实验组血沉为(36.78±21.93)mm/h, C反应蛋白(CRP)为(31.74±25.76)mg/L,类风湿因子(RF)为(65.32±31.78)IU/ml,抗环瓜氨酸肽(CCP)抗体为(34.65±23.76)RU/ml;对照组血沉为(56.87±28.94)mm/h,CRP为(49.87±26.42)mg/L, RF为(98.76±56.42)IU/ml,抗CCP抗体为(57.83±26.89)RU/ml。治疗后,实验组血沉、CRP、RF及抗CCP抗体均低于对照组,差异有统计学意义(t=8.748、7.768、8.165、10.214,P<0.05)。治疗后,实验组视觉模拟评分法(VAS)评分为(2.43±0.45)分,低于对照组的(3.68±1.65)分,差异有统计学意义(t=11.556, P<0.05)。实验组总不良反应发生率略低于对照组,但差异无统计学意义(P>0.05)。结论 甲氨蝶呤片联合艾拉莫德片治疗类风湿关节炎患者效果显著,可在临床推广应用。Objective To analyze the effect of methotrexate tablets combined with iguratimod tablets on rheumatoid arthritis. Methods A total of 500 patients with rheumatoid arthritis as the research subjects were randomly divided into a control group and an experimental group, with 250 cases in each group. The control group was treated with methotrexate tablets, and the experimental group was treated with methotrexate tablets combined with iilamod tablets. The therapeutic effects, laboratory indicators, pain scores, and occurrence of adverse reactions were compared between the two groups. Results The total effective rate of treatment in the experimental group was 95.20%, which was higher than 90.00% in the control group, and the difference was statistically significant(P<0.05). After treatment, in the experimental group, the erythrocyte sedimentation rate was(36.78±21.93) mm/h, the C-reactive protein(CRP) was(31.74±25.76) mg/L, the rheumatoid factor(RF)was(65.32±31.78) IU/ml, and the anti-Cyclic citrullinated peptide(CCP) antibody was(34.65±23.76) RU/ml;in the control group, the ESR was(56.87±28.94) mm/h, the CRP was(49.87±26.42) mg/L, the RF was(98.76±56.42) IU/ml, and the anti-CCP antibody was(57.83±26.89) RU/ml. After treatment, the ESR, CRP, RF and anti-CCP antibody in the experimental group were lower than those in the control group, and the differences were all statistically significant(t=8.748, 7.768, 8.165, 10.214;P<0.05). After treatment, the visual analogue scale(VAS) score of the experimental group was(2.43±0.45) points, which was lower than(3.68±1.65) points of the control group, and the difference was statistically significant(t=11.556, P<0.05). The incidence of total adverse reactions in the experimental group was slightly lower than that in the control group, but the difference was not statistically significant(P>0.05). Conclusion Methotrexate tablets in combination with iguratimod tablets are very effective for patients with rheumatoid arthritis, which can be promoted and applied in clinical practi

关 键 词：甲氨蝶呤片 艾拉莫德片 类风湿关节炎 实验室指标 疼痛评分 

分 类 号：R593.22[医药卫生—内科学]